HOME Top Market Reports Top 10 Drug Delivery Technologies Market (Topical, Oral Time Release/Sustained Release, Targeted Delivery, Encapsulation, Aerosol/Inhalation, Transdermal, Implants, Injectable, Liposomal, Pegylation) - Global Trends, Challenges & Forecasts up till 2015

Top 10 Drug Delivery Technologies Market (Topical, Oral Time Release/Sustained Release, Targeted Delivery, Encapsulation, Aerosol/Inhalation, Transdermal, Implants, Injectable, Liposomal, Pegylation) - Global Trends, Challenges & Forecasts up till 2015

By: marketsandmarkets.com
Publishing Date: February 2011
Report Code: BT 1039

Discount on Reports  

  Speak to Analyst Enquiry Before Buying
 
purchase report
download pdf  request for customisation


STUDY GOALS AND OBJECTIVES

  • To define and measure drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics and others.
  • To identify major drivers and restraints of the market
  • To evaluate comprehensively all drug delivery technologies and benchmark them against various parameters to identify top ten technologies.
  • To identify and analyze comprehensively market structure with respect to the factors influencing market growth and industry specific challenges.
  • To analyze trends and forecasts of drug delivery market and its segments
  • To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.
  • To analyze opportunities in the market for stakeholders
  • To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market
  • To understand regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.
  • To analyze and forecast revenues of market segments with respect to geographies (North America, Europe, Asia and Rest of the World
  • To provide comprehensive analysis of top players in the drug delivery technology market.
  • To effectively scope out and justify evaluation and provide sufficient basis of ranking top ten drug delivery technologies.

REASONS FOR DOING THE STUDY

More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body (pharmacokinetics) therefore signifying the importance of drug delivery systems. Rapid enhancements in drug discovery technologies have lead to developments in proteomics and genomics and had a greater impact on drug delivery technology market. The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.

SCOPE AND FORMAT

Top 10 Drug Delivery Technologies Market research report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are:

  • Oral drug delivery technologies
  • Injectable drug delivery technologies
  • Pulmonary drug delivery technologies
  • Transdermal drug delivery technologies
  • Other drug delivery technologies

The report also focuses on the emerging drug delivery technologies and mechanisms.

INTENDED AUDIENCES

  • Drug delivery technology – manufacturers, suppliers and dealers
  • Pharmaceutical and biotech companies
  • Healthcare providers
  • Potential investors in the drug delivery technology market

INFORMATION SOURCES

Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides 40 companies. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.

TABLE OF CONTENTS

EXECUTIVE SUMMARY
 OBJECTIVE
 MARKET SCENARIO
 EMERGING TECHNOLOGIES

1 INTRODUCTION
  1.1 KEY TAKE-AWAYS
  1.2 REPORT DESCRIPTION
  1.3 MARKETS COVERED
  1.4 STAKEHOLDERS
  1.5 RESEARCH METHODOLOGY

2 SUMMARY

3 MARKET OVERVIEW
  3.1 INTRODUCTION
  3.2 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE
  3.3 STAKEHOLDERS
  3.4 CHALLENGES
      3.4.1 GOVERNMENT REGULATIONS
      3.4.2 PRICING PRESSURE, REIMBURSEMENTS, & THIRD-PARTY DEPENDENCE
      3.4.3 PATENT LITIGATIONS
      3.4.4 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES
  3.5 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS
  3.6 PATENT ANALYSIS

4 MARKET DYNAMICS
  4.1 INTRODUCTION
  4.2 DRIVERS
      4.2.1 PATENT EXPIRATION OF DRUGS
      4.2.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS & BIOPHARMACEUTICALS
      4.2.3 REDUCE ATTRITION RATES & FASTER DRUG DISCOVERY/DEVELOPMENT PROCESSES
      4.2.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY
      4.2.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES
  4.3 RESTRAINTS
      4.3.1 DRUG FAILURES RAISE CONCERNS ON ROI
      4.3.2 U.S. HEALTHCARE REFORMS
  4.4 OPPORTUNITIES
      4.4.1 HOME-CARE DRUG DELIVERY DEVICES & SELF-ADMINISTRATION
      4.4.2 NICHE THERAPEUTIC AREAS
      4.4.3 WELLNESS PRODUCTS

5 CONTROLLED RELEASE TECHNOLOGY
  5.1 INTRODUCTION
      5.1.1 KEY MARKET PLAYERS
  5.2 DRIVERS
      5.2.1 CONTROLLED RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS
      5.2.2 ONCE-A-DAY FORMULATIONS
      5.2.3 COST EFFECTIVE
  5.3 RESTRAINTS
      5.3.1 LIMITED NUMBER OF MATERIALS
      5.3.2 TECHNICAL BARRIERS
  5.4 OPPORTUNITIES
      5.4.1 PARTICULATE & CHRONOPHARMACOKINETIC SYSTEMS
      5.4.2 MUCOADHESIVE DRUG DELIVERY
  5.5 BIODEGRADABLE POLYMERS
  5.6 HYDROGEL
  5.7 MULTIPARTICULATE BEAD SYSTEMS
  5.8 ION EXCHANGE RESINS
  5.9 OSMOTIC PRESSURE CONTROLLED SYSTEMS
  5.10 DISSOLUTION/DIFFUSION SYSTEMS
       5.10.1 MATRIX SYSTEMS
       5.10.2 RESERVOIR SYSTEMS
  5.11 OTHERS
  5.12 REGULATORY ENVIRONMENT
  5.13 CONTROLLED RELEASE VS IMMEDIATE RELEASE FORMULATIONS
  5.14 INNOVATIONS IN CONTROLLED RELEASE TECHNOLOGIES
  5.15 BURNING ISSUES
  5.16 WINNING IMPERATIVES
  5.17 COMPETITIVE DEVELOPMENTS

6 TARGETED DELIVERY
  6.1 INTRODUCTION
      6.1.1 KEY MARKET PLAYERS
  6.2 DRIVERS & RESTRAINTS
      6.2.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS
      6.2.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR
      6.2.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS
  6.3 OPPORTUNITY
      6.3.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS
  6.4 TARGETING LIGANDS
      6.4.1.1 Antibody fragment drug conjugate delivery
      6.4.1.2 Antibody directed enzyme prodrug targeted delivery
      6.4.1.3 Peptide-targeted delivery
      6.4.1.4 Small molecule conjugate delivery
      6.4.1.5 Others
  6.5 NON-BIOLOGICAL TARGETING PLATFORMS
  6.6 CURRENTLY MARKETED TARGETED THERAPIES
  6.7 IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS
  6.8 INNOVATIONS
  6.9 INDUSTRY INSIGHTS
  6.10 WINNING IMPERATIVES

7 ENCAPSULATION TECHNOLOGIES
  7.1 INTRODUCTION
      7.1.1 KEY MARKET PLAYERS
  7.2 DRIVERS & RESTRAINTS
      7.2.1 ENHANCED BIOAVAILABILITY
      7.2.2 EXTENSIVE USAGE IN TASTE MASKING & FASTER DISSOLVING PILLS
      7.2.3 ECONOMICALLY FEASIBLE
      7.2.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES
  7.3 OPPORTUNITY
      7.3.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS
  7.4 TASTE MASKING
  7.5 FAST DISSOLVING PILLS
  7.6 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
  7.7 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY
  7.8 INDUSTRY INSIGHTS
  7.9 WINNING IMPERATIVES
  7.10 COMPETITIVE DEVELOPMENTS

8 TOPICAL FORMULATIONS
  8.1 INTRODUCTION
      8.1.1 KEY MARKET PLAYERS
  8.2 DRIVERS & RESTRAINTS
      8.2.1 BURN & WOUND TREATMENT
      8.2.2 BYPASSING FIRST PASS EFFECT
      8.2.3 CONVENIENCE FACTOR
      8.2.4 USAGE IN LIMITED THERAPEUTIC AREAS
  8.3 OPPORTUNITY
      8.3.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS
  8.4 GEL TECHNOLOGY
  8.5 MICROEMULSIONS
  8.6 BIPHASIC SYSTEM
  8.7 OTHERS
  8.8 INDUSTRY INSIGHTS
  8.9 WINNING IMPERATIVES
  8.1 COMPETITIVE DEVELOPMENTS

9 INHALER TECHNOLOGY
  9.1 INTRODUCTION
      9.1.1 KEY MARKET PLAYERS
  9.2 DRIVERS & RESTRAINTS
      9.2.1 INCREASE IN ASTHMA & COPD PATIENTS
      9.2.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN
      9.2.3 EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY
      9.2.4 FAILURE OF EXUBERA
  9.3 OPPORTUNITY
      9.3.1 APPLICATION IN NON-RESPIRATORY CONDITIONS
  9.4 DRY POWDER INHALERS
  9.5 METERED DOSE INHALERS
  9.6 NEBULIZERS
  9.7 EVOLUTION OF INHALER DEVICES
  9.8 REGULATORY ENVIRONMENT
  9.9 TECHNOLOGY INNOVATIONS
  9.10 INDUSTRY INSIGHTS
  9.11 WINNING IMPERATIVES
  9.12 COMPETITIVE DEVELOPMENTS

10 INJECTABLE DRUG DELIVERY
   10.1 INJECTION DEVICES
        10.1.1 KEY MARKET DYNAMICS
               10.1.1.1 Drivers
                        10.1.1.1.1 Growth of self-administration therapies
                        10.1.1.1.2 Needle-stick legislation
                        10.1.1.1.3 Increasing acceptance by physicians and patients
                        10.1.1.1.4 Reducing cost of treatment
               10.1.1.2 Restraints
                        10.1.1.2.1 Need of new drug formulation
               10.1.1.3 Opportunities
                        10.1.1.3.1 Product differentiation through added functional features
                        10.1.1.3.2 Expansion to new areas
   10.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE
   10.3 KEY DEVELOPMENTS
        10.3.1 DEVELOPMENT OF MICRONEEDLES
        10.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS
   10.4 CONVENTIONAL INJECTABLES
   10.5 PREFILLED SYRINGES (PFS)
        10.5.1 KEY MARKET DYNAMICS
               10.5.1.1 Drivers
                        10.5.1.1.1 Growing market for self-injection devices
                        10.5.1.1.2 Wastage control and cost reduction through less overfill
                        10.5.1.1.3 Ease of manufacture & convenient usability
               10.5.1.2 Restraints
                        10.5.1.2.1 Threat from needle-free devices
                        10.5.1.2.2 Protecting product quality
        10.5.2 GLASS PFS
        10.5.3 PLASTIC PFS
   10.6 SELF INJECTION DEVICES
        10.6.1 AUTO INJECTORS
               10.6.1.1 Reusable auto-injectors
               10.6.1.2 Disposable auto-injectors
        10.6.2 PEN INJECTORS
               10.6.2.1 Reusable pen injectors
               10.6.2.2 Disposable pen injectors
        10.6.3 NEEDLE-FREE INJECTORS (NFI)
               10.6.3.1 Reusable NFIs
               10.6.3.2 Disposable NFIs
10.7 OTHERS

11 TRANSDERMAL PATCH
   11.1 INTRODUCTION
        11.1.1 KEY MARKET PLAYERS
   11.2 DRIVERS
        11.2.1 REDUCED SIDE EFFECTS & BETTER EFFICACY
        11.2.2 CONVENIENT & LESS PAINFUL
   11.3 RESTRAINTS
        11.3.1 RECALL OF DURAGESIC & NEGATIVE PUBLICITY OF ORTHO EVRA PATCH
        11.3.2 LOW SKIN PERMEABILITY OF DRUGS
   11.4 OPPORTUNITIES
        11.4.1 NEW PRODUCTS
               11.4.1.1 Contraceptive patch
               11.4.1.2 Pain management patch
               11.4.1.3 Estrogen/hormone replacement patch
   11.5 INDUSTRY INSIGHTS
   11.6 WINNING IMPERATIVES
   11.7 COMPETITIVE DEVELOPMENTS

12 IMPLANTABLE DRUG DELIVERY
   12.1 INTRODUCTION
   12.2 DRIVERS & RESTRAINTS
        12.2.1 SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT
        12.2.2 DOSING ADMINISTRATION NOT REQUIRED
        12.2.3 INCONVENIENCE
   12.3 OPPORTUNITY
        12.3.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS
   12.4 CORONARY (DRUG ELUTING) STENTS
   12.5 IMPLANTABLE INFUSION PUMPS
   12.6 OCULAR IMPLANTS & OTHERS
   12.7 INDUSTRY INSIGHTS
   12.8 WINNING IMPERATIVES

13 LIPOSOMAL DRUG DELIVERY
   13.1 INTRODUCTION
   13.2 DRIVERS & RESTRAINTS
        13.2.1 ENHANCED USAGE IN CANCER
        13.2.2 EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS
        13.2.3 SIDE EFFECTS
   13.3 OPPORTUNITY
        13.3.1 NANOSCALE LIPOSOME DRUG DELIVERY
   13.4 INDUSTRY INSIGHTS
   13.5 WINNING IMPERATIVES
   13.6 COMPETITIVE DEVELOPMENTS

14 PEGYLATION TECHNOLOGIES
   14.1 INTRODUCTION
   14.2 DRIVERS & RESTRAINTS
        14.2.1 BIOLOGICAL DRUGS
        14.2.2 ENHANCED PHARMACOKINETIC PROPERTIES & REDUCED DOSAGE
        14.2.3 EXPENSIVE MANUFACTURING PROCEDURE
   14.3 OPPORTUNITY
        14.3.1 TECHNOLOGICAL ADVANCES
   14.4 INDUSTRY INSIGHTS
   14.5 WINNING IMPERATIVES

15 COMPETITIVE LANDSCAPE
   15.1 INTRODUCTION
   15.2 ANALYSIS OF TOP PLAYERS
        15.2.1 STRATEGY
        15.2.2 INJECTABLE DRUG DELIVERY DEVICES MARKET SHARE
               15.2.2.1 Top injectable drug delivery device companies & revenues, by segment
   15.3 WINNING IMPERATIVES
        15.3.1 ALLIANCES
        15.3.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY
        15.3.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS
   15.4 STRATEGIC RECOMMENDATIONS

16 GEOGRAPHIC ANALYSIS
   16.1 INTRODUCTION
   16.2 NORTH AMERICA
   16.3 EUROPE
   16.4 ASIA
   16.5 REST OF THE WORLD (ROW)
   16.6 DECISION SUPPORT DATABASE

17 COMPANY PROFILES
   17.1 3M COMPANY
        17.1.1 OVERVIEW
        17.1.2 FINANCIALS
        17.1.3 PRODUCTS & SERVICES
        17.1.4 STRATEGY
        17.1.5 DEVELOPMENTS
   17.2 ALKERMES, INC
        17.2.1 OVERVIEW
        17.2.2 FINANCIALS
        17.2.3 PRODUCTS & SERVICES
        17.2.4 STRATEGY
        17.2.5 DEVELOPMENTS
   17.3 ALTEA THERAPEUTICS INC.
        17.3.1 OVERVIEW
        17.3.2 PRODUCTS & SERVICES
        17.3.3 STRATEGY
        17.3.4 DEVELOPMENTS
   17.4 ANTARES PHARMA INC.
        17.4.1 OVERVIEW
        17.4.2 FINANCIALS
        17.4.3 PRODUCTS & SERVICES
        17.4.4 STRATEGY
        17.4.5 DEVELOPMENTS
   17.5 A.P. PHARMA, INC.
        17.5.1 OVERVIEW
        17.5.2 FINANCIALS
        17.5.3 PRODUCTS & SERVICES
        17.5.4 STRATEGY
        17.5.5 DEVELOPMENTS
   17.6 APPLIED PHARMA
        17.6.1 OVERVIEW
        17.6.2 PRODUCTS & SERVICES
        17.6.3 STRATEGY
        17.6.4 DEVELOPMENTS
   17.7 ARADIGM CORPORATION
        17.7.1 OVERVIEW
        17.7.2 FINANCIALS
        17.7.3 PRODUCTS & SERVICES
        17.7.4 STRATEGY
        17.7.5 DEVELOPMENTS
   17.8 B AXTER BIOPHARMA
        17.8.1 OVERVIEW
        17.8.2 PRODUCTS & SERVICES
        17.8.3 FINANCIALS
        17.8.4 STRATEGY
        17.8.5 DEVELOP0MENTS
   17.9 BECTON, DICKINSON AND COMPANY
        17.9.1 OVERVIEW
        17.9.2 PRODUCT & SERVICES
        17.9.3 FINANCIALS
        17.9.4 STRATEGY
        17.9.5 DEVELOPMENTS
  17.10 BIOJECT INC.
        17.10.1 OVERVIEW
        17.10.2 FINANCIALS
        17.10.3 PRODUCTS & SERVICES
        17.10.4 STRATEGY
        17.10.5 DEVELOPMENTS
  17.11 BIOVAIL CORPORATION  (VALEANT PHARMACEUTICALS INTERNATIONAL INC.)
        17.11.1 OVERVIEW
        17.11.2 PRODUCTS & SERVICES
        17.11.3 FINANCIALS
        17.11.4 STRATEGY
        17.11.5 DEVELOPMENTS
  17.12 CIMA LABS INC.
        17.12.1 OVERVIEW
        17.12.2 PRODUCTS & SERVICES
        17.12.3 STRATEGY
        17.12.4 DEVELOPMENTS
  17.13 ELAN CORPORATION PLC.
        17.13.1 OVERVIEW
        17.13.2 FINANCIALS
        17.13.3 PRODUCTS & SERVICES
        17.13.4 STRATEGY
        17.13.5 DEVELOPMENTS
  17.14 ENDO PHARMACEUTICALS
        17.14.1 OVERVIEW
        17.14.2 FINANCIALS
        17.14.3 PRODUCTS & SERVICES
        17.14.4 STRATEGY
        17.14.5 DEVELOPMENTS
  17.15 EURAND PHARMACEUTICALS
        17.15.1 OVERVIEW
        17.15.2 FINANCIALS
        17.15.3 PRODUCTS & SERVICES
        17.15.4 STRATEGY
        17.15.5 DEVELOPMENTS
  17.16 FLAMEL TECHNOLOGIES, INC
        17.16.1 OVERVIEW
        17.16.2 FINANCIALS
        17.16.3 PRODUCTS & SERVICES
        17.16.4 STRATEGY
        17.16.5 DEVELOPMENTS
  17.17 JOHNSON & JOHNSON LTD.
        17.17.1 OVERVIEW
        17.17.2 FINANCIALS
        17.17.3 PRODUCTS & SERVICES
        17.17.4 STRATEGY
        17.17.5 DEVELOPMENTS
 17.1 8 KV PHARMACEUTICAL
        17.18.1 OVERVIEW
        17.18.2 FINANCIALS
        17.18.3 PRODUCTS & SERVICES
        17.18.4 STRATEGY
        17.18.5 DEVELOPMENTS
  17.19 LABOPHARM INC.
        17.19.1 OVERVIEW
        17.19.2 FINANCIALS
        17.19.3 PRODUCTS & SERVICES
        17.19.4 STRATEGY
        17.19.5 DEVELOPMENTS
  17.20 NANOPASS TECHNOLOGIES LTD.
        17.20.1 OVERVIEW
        17.20.2  PRODUCTS & SERVICES
        17.20.3 STRATEGY
        17.20.4DEVELOPMENTS
  17.21 NEKTAR THERAPEUTICS
        17.21.1 OVERVIEW
        17.21.2 FINANCIALS
        17.21.3 PRODUCTS & SERVICES
        17.21.4 STRATEGY
        17.21.5 DEVELOPMENTS
  17.22 QLT INC.
        17.22.1 OVERVIEW
        17.22.2 FINANCIALS
        17.22.3 PRODUCTS & SERVICES
        17.22.4 STRATEGY
        17.22.5 DEVELOPMENTS
        17.23 SKYEPHARMA PLC.
        17.23.1 OVERVIEW
        17.23.2 FINANCIALS
        17.23.3 PRODUCTS & SERVICES
        17.23.4 STRATEGY
        17.23.5 DEVELOPMENTS
  17.24 SURMODICS, INC.
        17.24.1 OVERVIEW
        17.24.2 PRODUCTS & SERVICES
        17.24.3 FINANCIALS
        17.24.4 STRATEGY
        17.24.5 DEVELOPMENTS
  17.25 VECTURA GROUP PLC
        17.25.1 OVERVIEW
        17.25.2 FINANCIALS
        17.25.3 PRODUCTS & SERVICES
        17.25.4 STRATEGY
        17.25.5 DEVELOPMENTS
  17.26 YPSOMED HOLDING AG
        17.26.1 OVERVIEW
        17.26.2 FINANCIALS
        17.26.3 PRODUCTS & SERVICES
        17.26.4 STRATEGY
        17.26.5 DEVELOPMENTS
  17.27 ZOGENIX, INC.
        17.27.1 OVERVIEW
        17.27.2 PRODUCTS & SERVICES
        17.27.3 STRATEGY
        17.27.4 DEVELOP0MENTS

U.S. PATENTS
EUROPE PATENTS
JAPAN PATENTS

LIST OF TABLES

1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS
2008 – 2015 ($MILLION)
2 DRUGS SET FOR PATENT EXPIRATION (2010 – 2012)
3 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
4 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015  ($MILLION)
5 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
7 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY
2008 – 2015 ($MILLION)
8 GLOBAL HYDROGEL MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
9 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
10 GLOBAL ION EXCHANGE RESINS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
11 GLOBAL OSMOTIC PRESSURE CONTROLLED SYSTEMS MARKET,
BY GEOGRAPHY 2008 – 2015 ($MILLION)
12 GLOBAL DISSOLUTION/DIFFUSION SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
13 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
14 GLOBAL RESERVOIR SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
15 GLOBAL OTHER CONTROLLED RELEASE SYSTEMS MARKET,
BY GEOGRAPHY 2008 – 2015 ($MILLION)
16 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
17 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
18 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
19 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
20 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
21 GLOBAL ANTIBODY FRAGMENT CONJUGATE DELIVERY MARKET,
BY GEOGRAPHY 2008 – 2015 ($MILLION)
22 GLOBAL ANTIBODY ENZYME DIRECTED PRODRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
23 GLOBAL PEPTIDE TARGETED DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
24 GLOBAL SMALL MOLECULE CONJUGATE DELIVERY MARKET,
BY GEOGRAPHY 2008 – 2015 ($MILLION)
25 GLOBAL OTHER TARGETING LIGANDS BASED DELIVERY MARKET,
BY GEOGRAPHY 2008 – 2015 ($MILLION)
26 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET,
BY GEOGRAPHY 2008 – 2015 ($MILLION)
27 GLOBAL ENCAPSULATION TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
28 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
29 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
30 GLOBAL ENCAPSULATION MARKET IN TASTE MASKING, BY GEOGRAPHY 2008 – 2015 ($MILLION)
31GLOBAL ENCAPSULATION MARKET IN FAST DISSOLVING,
BY GEOGRAPHY 2008 – 2015 ($MILLION)
32 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
33 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY
(2008 – 2015)
34 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
35 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
36 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
37 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
38 GLOBAL OTHER TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($ MILLION)
39 GLOBAL INHALER TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
40 GLOBAL INHALER TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
41 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
42 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY
2008 – 2015 ($MILLION)
43 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY
2008 – 2015 ($MILLION)
44 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
45 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
46 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET,
BY GEOGRAPHY 2008-2015 ($MILLION)
47 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
48 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
49 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
50 GLOBAL PREFILLED SYRINGES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
51 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS
2008 – 2015 ($MILLION)
52 GLOBAL SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY
2008 – 2015 ($MILLION)
53 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
54 GLOBAL AUTO INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
55 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
56 GLOBAL PEN INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
57 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY
58 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
59 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY GEOGRAPHY
2008 – 2015 ($MILLION)
60 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
61 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET,
BY PRODUCTS (2008 – 2015)
62GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET,
BY GEOGRAPHY 2008 – 2015 ($MILLION)
63 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
64 GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
65 GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY
2008 – 2015 ($MILLION)
66 GLOBAL OCULAR IMPLANTS & OTHERS MARKET, BY GEOGRAPHY
2008 – 2015 ($MILLION)
67 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY
2008 – 2015 ($MILLION)
68 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
69 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY
2008 – 2015 ($MILLION)
70 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
71 REVENUE ANALYSIS (2008 – 2009)
72 ELAN TOTAL REVENUES BY DRUG (2008 – 2010)
73 ALKERMES TOTAL REVENUES, BY DRUG (2008 – 2010)
74 R&D EXPENDITURE (2008 – 2009)
75 ELAN’S PIPELINE DRUGS
76 BIOVAIL’S PIPELINE DRUGS
77 ALKERMES’S PIPELINE DRUGS
78 NEKTAR’S PIPELINE DRUGS
79 SKYE PHARMA’S PIPELINE DRUGS
80 TOP COMPANIES & THEIR STRATEGIES
81 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENT ($MILLION)
82 BAXTER BIOPHARMA REVENUES, BY SEGMENT
83 YPSOMED - TOTAL REVENUES, BY SEGMENT ($MILLION)
84 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION
(2008 – 2015)
85 NORTH AMERICAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET,
BY SEGMENT
86 EUROPEAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET,
BY SEGMENT
87 ASIAN TOP 10 DRUG DELIVERY TECHNOLOGIES
88 REST OF THE WORLD TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
89 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY (2009)
90 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY (2009)
91 DIABETES PREVALENCE, BY GEOGRAPHY (2009)
92 CANCER PREVALENCE, BY GEOGRAPHY (2009)
93 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY (2009)
94 ANEMIA PREVALENCE, BY GEOGRAPHY (2009)
95 HEPATITIS-C PREVALENCE, BY GEOGRAPHY (2009)
96 CROHN’S DISEASE PREVALENCE, BY GEOGRAPHY (2009)
97 PSORIASIS PREVALENCE, BY GEOGRAPHY (2009)
98 TOTAL REVENUES & R&D EXPENDITURE
99 TOTAL REVENUES, BY GEOGRAPHY
100 TOTAL REVENUES (2006 – 2010)
101 SEGMENT SPECIFIC REVENUES ($MILLION)
102 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
103 TOTAL REVENUES, BY GEOGRAPHY
104 REVENUES, BY SEGMENTS
105 TOTAL REVENUES & NET INCOME ($MILLION)
106 TOTAL REVENUES (2007 – 2009)
107 BAXTER BIOPHARMA – TOTAL REVENUES & R&D EXPENSES ($MILLION)
108 BAXTER BIOPHARMA – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
109 BAXTER BIOPHARMA – TOTAL REVENUES, BY SEGMENTS ($MILLION)
110 BAXTER BIOPHARMA – TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENTS ($MILLION)
111 BECTON DICKINSON – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
112 BECTON DICKINSON – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
113 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENTS ($MILLION)
114 BECTON DICKINSON – TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENTS ($MILLION)
115 TOTAL REVENUES & R&D EXPENDITURE
116 REVENUES, BY SEGMENTS ($MILLION)
117 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
118 U.S REVENUES OF BIOVAIL, BY PRODUCTS ($MILLION)
119 TOTAL PRODUCT REVENUES OF BIOVAIL PHARMACEUTICALS CANADA
120 TOTAL REVENUES & R&D EXPENDITURE
121 REVENUES, BY PRODUCTS
122 TOTAL REVENUES & R&D EXPENDITURE
123 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
124 PRODUCT SALES, BY THERAPEUTIC AREA
125 REVENUES & R&D EXPENDITURE
126 TOTAL REVENUES & R&D EXPENDITURE
127 REVENUES, BY BUSINESS SEGMENTS
128 REVENUES, BY PRODUCTS
129 REVENUES, BY GEOGRAPHY ($MILLION)
130 TOTAL REVENUES & EXPENDITURE
131 TOTAL REVENUES & R&D EXPENDITURE
132 NEKTAR – TOTAL REVENUES & R&D EXPENSES
133 NEKTAR – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
134 QLT – TOTAL REVENUES & R&D EXPENSES ($MILLION)
135 QLT – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
136 TOTAL REVENUES & R&D EXPENSES ($MILLION)
137 SURMODICS INC. – TOTAL REVENUES & R&D EXPENSES ($MILLION)
138 SURMODICS INC. – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
139 SURMODICS INC. – TOTAL REVENUES, BY SEGMENTS ($MILLION)
140 TOTAL REVENUES & R&D EXPENDITURE
141 YPSOMED - TOTAL REVENUES & R&D EXPENSES ($MILLION)
142 YPSOMED - TOTAL REVENUES, BY SEGMENTS ($MILLION)

LIST OF FIGURES

1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES
2 TOP 10 DRUG DELIVERY TECHNOLOGIES – MARKET SHARE
3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY
4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN  A DRUG LIFE CYCLE
5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS
6 DRUG DELIVERY MARKET STAKEHOLDERS
7 IMPACT OF MARKET DRIVERS & RESTRAINTS
8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES
9 PATENT ANALYSIS, BY SEGMENTS (2004 – 2009)
10 PATENT ANALYSIS, BY ASSIGNEE (2004 – 2009)
11 COMMON REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS
12 EVOLUTION OF CONTROLLED RELEASE TECHNOLOGIES
13 CONTROLLED RELEASE VS IMMEDIATE RELEASE
14 TARGETED THERAPY TYPES
15 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
16 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY
17 EVOLUTION OF INHALER TECHNOLOGY
18 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE
19 COMPETITIVE DEVELOPMENTS (2007 – JUNE 2010)
20 COMPETITIVE DEVELOPMENTS, BY SEGMENTS (2007 – JUNE 2010)
21 REVENUE ANALYSIS (2008 – 2009)
22 CONTROLLED RELEASE, DRUG FORMULATION – MARKET SHARE
23 R&D EXPENDITURE (2008 – 2009)
24 INJECTABLE DRUG DELIVERY DEVICES, MARKET SHARE
25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – NORTH AMERICA
27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – EUROPE
28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ASIA
29 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ROW

Top 10 Drug Delivery Technologies Market To Grow Exponentially

The increasing demand for effective delivery of novel biopharmaceuticals is driving the growth of the global top 10 drug delivery technologies market. Patent expirations of drugs, need for faster drug development and greater drug approvals are further fuelling market growth. The global top 10 drug delivery technologies market is expected to grow from $43.8 billion in 2009 to $81.5 billion in 2015, at an estimated CAGR of 11% from 2010 to 2015. The time release technologies market commands the largest share around 19% of the overall top 10 drug delivery technologies market, owing to immense popularity of once-daily formulations.

Drug delivery technologies are revenue boosters for the pharmaceutical industry as they enhance drug life cycle in the market by extending patent rights, adding a competitive edge to the drug by enhancing their safety and efficacy. Further, expansion of the applications of non conventional modes of drug delivery such as pulmonary, nasal and transdermal in disease conditions other than respiratory and skin, especially in chronic disease conditions such as diabetes, CNS are also boosting the market. In addition, innovations such as microneedle transdermal patches and novel intelligent inhalers are also adding to the market growth. However, recent drug failures such as Exubera by Pfizer is a hindrance for the market.

Prominent industry participants include Elan, Biovail, Nektar and Alkermes. Pure drug delivery technology providers are gradually shifting towards specialty pharmaceuticals with focus on CNS and Cancer. Further, industry players are focusing on developing alternatives that are not only safe and effective but also are convenient in terms of drug administration and dosing regimen.

Currently, market players are focusing in the development and commercialization of new drugs through agreements and collaborations which therefore accounted for the highest share of the total competitive developments in the global top 10 drug delivery technologies market from 2007 to June 2010.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports